DiCE Molecules Overview

  • Founded
  • 2013
Founded
  • Status
  • Public
  • Employees
  • 35
Employees
  • Stock Symbol
  • DICE
Stock Symbol
  • Share Price
  • $29.53
  • (As of Monday Closing)

DiCE Molecules General Information

Description

DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas.

Contact Information

Ownership Status
Publicly Held
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Stock Exchange
NAS
Primary Office
  • 279 East Grand Avenue
  • Suite 300, Lobby B
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

DiCE Molecules Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

DiCE Molecules Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$29.53 $26.70 $23.16 - $40.50 $971M 36.4M 243K -$1.22

DiCE Molecules Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2021 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
Revenue 2,000 2,000 863 5,775
EBITDA (23,168) (12,841)
Net Income (23,739) (12,938)
Total Assets 63,861 31,181
Total Debt 98 222
Public Fundamental Data provided by Morningstar, Inc. disclaimer

DiCE Molecules Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore DiCE Molecules‘s full profile, request access.

Request a free trial

DiCE Molecules Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore DiCE Molecules‘s full profile, request access.

Request a free trial

DiCE Molecules Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary technology platform to build a pipeline of n
Drug Discovery
South San Francisco, CA
35 As of 2021
00000
0000 0000-00-00
00000000 00000

00000000

quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
0000 000000000
Middleton, WI
00 As of 0000
000.00
0000000000 0 000.00

00000 00

quat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla p
0000 00000000
South San Francisco, CA
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DiCE Molecules Competitors (94)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Centrose Venture Capital-Backed Middleton, WI 00 000.00 0000000000 0 000.00
00000 000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
0000000 0000000000 Venture Capital-Backed Boston, MA 00 00000 00000000 00000
000000 00000000000 Venture Capital-Backed Ghent, Belgium 00 00000 00000000000 00000
000000 Venture Capital-Backed Pomona, CA 0 00000 0000000000 0 00000
You’re viewing 5 of 94 competitors. Get the full list »

DiCE Molecules Patents

DiCE Molecules Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2019523646-A Route determination methods, compositions, and uses thereof Pending 05-Jun-2016 00000000000
US-20170348666-A1 Methods of routing, compositions and uses thereof Abandoned 05-Jun-2016 00000000000
EP-3464590-A4 Methods of routing, compositions and uses thereof Withdrawn 05-Jun-2016 00000000000 0
EP-3464590-A1 Methods of routing, compositions and uses thereof Withdrawn 05-Jun-2016 00000000000
EP-3359640-A4 Methods of estimating logd of tagged combinatorial library compounds Withdrawn 09-Oct-2015 G01N33/92 0

DiCE Molecules Executive Team (7)

Name Title Board Seat Contact Info
J. Judice Ph.D Chief Executive Officer & Board Member
Scott Robertson Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
John Jacobsen Ph.D Chief Scientific Officer
John Bedbrook Ph.D Co-Founder & Board Member
Pehr Harbury Ph.D Co-Founder & Board Member
You’re viewing 5 of 7 executive team members. Get the full list »

DiCE Molecules Board Members (11)

Name Representing Role Since
Geeta Vemuri Ph.D Agent Capital Board Observer 000 0000
J. Judice Ph.D DiCE Molecules Chief Executive Officer & Board Member 000 0000
Jake Simson Ph.D Self Board Member 000 0000
James Scopa JD Self Board Member 000 0000
John Bedbrook Ph.D DiCE Molecules Co-Founder & Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

DiCE Molecules Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DiCE Molecules Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore DiCE Molecules‘s full profile, request access.

Request a free trial